Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Contigen Bard is approvable

This article was originally published in The Gray Sheet

Executive Summary

Bard and Collagen Corp. receive FDA approvable letter March 19 for the jointly developed bovine collagen urinary stress incontinence product. Bard says the letter requests "routine" information on labeling, clinical data and postmarket surveillance studies. If approved by the agency, Contigen Bard would be the first injectable urinary stress incontinence product on the U.S. market. Under a 1987 agreement, Collagen will manufacture the product and supply it in bulk to Bard, which will package and distribute it under a worldwide, exclusive marketing license. Upon FDA approval, Bard "will conduct FDA-required physician training and then begin a full commercial launch," the company says in a March 22 release. The premarket approval application for Contigen Bard was initially submitted in March 1989 and received an approvable recommendation from FDA's gastroenterology-urology devices panel in October 1990; the PMA was subsequently amended to respond to FDA data requests in 1991 and the fall of 1992 ("The Gray Sheet" Oct. 26, p. 15).

You may also be interested in...



Regulatory Blessings Helping China CAR-Ts March Closer To Global Cancer Patients?

A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.

Polpharma Pursues Tysabri Through Antelope Trial

The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.

EU Guidance Document To Ensure Devices Are Assessed By Appropriately-Trained Reviewers

How do notified bodies ensure that their personnel, and the teams they allocate for conformity assessment of medical devices, have the precise knowledge and expertise needed? A new EU document gives guidance on this.

UsernamePublicRestriction

Register

MT000396

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel